NCT06395194 - Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension | Biotech Hunter

Enrollment

15,313

Participants

Timeline

Start Date

September 27, 1997

Primary Completion Date

September 5, 2003

Study Completion Date

December 5, 2003

Conditions

Essential Hypertension

Interventions

DRUG

Cardiac outcomes on treatment with valsartan

"Patients who already were on treatment, discontinued their previous antihypertensive medications when randomized to one of the trial's masked study arms (valsartan or amlodipine) without a run-in phase (rolled over). Valsartan treatment started at a dosage of 80 mg daily. If BP did not reach \<140/90 mmHg, the valsartan dose was doubled to 160 mg, and then hydrochlorothiazide (12.5 mg and 25 mg daily) and other antihypertensive drugs were added in sequential steps."

DRUG

Cardiac outcomes on treatment with amlodipine

"Patients who already were on treatment, discontinued their previous antihypertensive medications when randomized to one of the trial's masked study arms (valsartan or amlodipine) without a run-in phase (rolled over). Amlodipine treatment started at 5 mg daily. If BP did not reach \<140/90 mmHg, the amlodipine dose was doubled to 10 mg, and then hydrochlorothiazide (12.5 mg and 25 mg daily) and other antihypertensive drugs were added in sequential steps."

All Listed Sponsors

collaborator

University of Oslo

OTHER

lead

Oslo University Hospital

OTHER